-transparent.png){kind=logo}
We used cycles of plasma exchange and intravenous cyclophosphamide to treat a patient who had chronic inflammatory demyelinating polyneuropathy with anti-myelin-associated glycoprotein/sulfoglucuronylparagloboside IgM antibody. After treatment, serum anti-sulfoglucuronylparagloboside IgM antibody titers were reduced significantly, and clear symptomatic improvement followed. The percentage of CD57-positive lymphocytes and natural killer cell activity had also returned to normal. Our findings indicate that serial measurements of these parameters are useful for monitoring treatment effect in this disease.
Related Publications
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
September 1998,
Annals of neurology,
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
January 2007,
Annales de biologie clinique,
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
May 2006,
Journal of the neurological sciences,
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
May 1996,
Muscle & nerve,
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
June 2006,
Revue neurologique,
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
January 2013,
Rinsho shinkeigaku = Clinical neurology,
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
February 2000,
Annals of neurology,
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
July 2006,
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
March 1999,
Journal of neuroimmunology,
Y Tagawa, and
N Yuki, and
A Ohnishi, and
K Hirata, and
S Hosokawa
October 2001,
Muscle & nerve,
